Abstract: An apparatus, containing: (I) an inlet section into which a liquid and optionally a gaseous reagent stream is fed, the inlet section containing a device, which nebulizes and/or vaporizes the liquid stream, the device optionally utilizing vapor and/or a gaseous hydrocarbon stream as propellant; (II) a mixing section containing a chamber having a cylindrical or truncated-conical geometry, which mixes the reagent stream exiting the inlet section (I), to form a reaction mixture; (III) a reaction section including i) a first structured catalytic bed a ii) a structured catalytic bed heating device, in which the reaction mixture exiting the mixing section (II) flows through each layer of the first structured catalytic bed with a contact time varying from 0.01 to 10 ms, to produce a mixture of reaction products; and IV) a cooling section of the mixture of reaction products leaving the reaction section (III).

Abstract: A process to use ferric sulphate equilibrium to reduce overall acid consumption and iron extraction, the process comprising the steps of: (i) sulphating; (ii) selective pyrolysis and (iii) selective dissolution.

Abstract: A mixture of urea, water and ammonium carbamate is formulated for use in the catalytic reduction of oxides of nitrogen in diesel exhaust. The mixtures may be formulated to optimize the amount of reductant in the mixture and the freezing point of the formulation. These formulations are especially useful in combination with Selective Catalytic Reduction systems and are well suited for use on heavy-duty trucks and heavy duty equipment used off-road. Some of these formations include between about 15.0 wt. % to about 40.0 wt. % urea; between about 15.0 wt. % to about 40.0 wt. % ammonium carbamate; and between about 40.0 wt. % to about 60.0 wt. % water. The formulation may be monitored for ammonia content and/or freezing point and the composition of the formulation may be adjusted to optimize the freezing point and ammonia content.

Abstract: The present invention relates to a method for exhaust gas after-treatment for essentially lean-burn internal combustion engines and also a corresponding advantageous exhaust gas after-treatment system. In particular, the present invention relates to reducing the proportion of the greenhouse gas N20 in the total exhaust gas from a corresponding internal combustion system using at least one NOx storage catalyst as exhaust gas purification element. The objective of the invention is to operate the N20 depletion catalyst located downstream of the NOx storage catalyst under lambda=<1 conditions when the N20 formed by the NOx storage catalyst reaches the N20 depletion catalyst.

Abstract: A catalytic converter apparatus for use in an exhaust system of an internal combustion engine includes a housing having a gas inlet and a gas outlet, and at least one catalytic substrate element disposed in the housing. The at least one substrate element is divided into a plurality of zones or sections, the zones at least partially separated from one another to inhibit heat flow. The zones can be at least partially separated with walls. The walls can include insulating material for reducing the mobility of heat radially outwardly. Each of the zones defines a generally separate flow passage connecting the inlet and outlet in fluid communication. The apparatus can heat more rapidly from a cold start compared with conventional catalytic converters.

Abstract: Disclosed are an exhaust gas treating apparatus and a treating method for a carbon dioxide capture process, in which harmful substances remaining in the exhaust gas discharged from the conventional flue-gas desulfurization process are additionally removed for efficient performance of the carbon dioxide capture process. According to the exhaust gas treating apparatus for a carbon dioxide capture process, it has the effects of minimizing the installation space of desulfurization equipment and reducing the process cost. In addition, by keeping the contaminants contained in the gas introduced in the carbon dioxide capture equipment below a proper level, absorption performance can be improved as degradation of the absorbent used in the carbon dioxide capture process is prevented. After all, it has an advantage of preventing the pollution by the exhaust gas discharged into the atmosphere.

Abstract: The present invention provides for process for inhibiting the levels of nitrogen oxides in process gas streams from sulfuric acid regeneration and sulfuric acid production plants. Partial oxidation of the nitrogen oxides is achieved by feeding a sub stoichiometric amount of ozone as to nitrogen oxides to the process gas stream.

Abstract: A catalytic composition is disclosed, which exhibits an X-ray amorphous oxide, with a spinel formula and highly dispersed crystals of ZnO, CuO, and optionally CeO2. The composition is useful in oxidative and adsorptive processes for removing sulfur from gaseous hydrocarbons.

Abstract: A method of making a semiconductor device, includes providing a graphene sheet, creating a plurality of nanoholes in the graphene sheet to form a graphene nanomesh, the graphene nanomesh including a plurality of carbon atoms which are formed adjacent to the plurality of nanoholes, passivating a dangling bond on the plurality of carbon atoms by bonding a passivating element to the plurality of carbon atoms, and doping the passivated graphene nanomesh by bonding a dopant to the passivating element.

Abstract: A preparation method of zinc manganese silicate is provided. The method includes the following steps: step 1, preparing silicon dioxide sol with distilled water, anhydrous ethanol and tetraethyl orthosilicate; step 2, preparing a mixture solution of a zinc salt and a manganese salt; step 3, adjusting the silicon dioxide sol to be neutral or acidic; step 4, adding the mixture solution of the zinc salt and the manganese salt into the silicon dioxide sol to form a gelatin; step 5, drying the gelatin, keeping the temperature, grinding, reducing with keeping the temperature in a reductive atmosphere to obtain zinc manganese silicate. The preparation method has simple technique and low equipment requirement. The particles of the zinc manganese silicate phosphor prepared by the method have a regular size, uniform shape and good luminescent performance.

Abstract: A method for manufacturing a polycrystalline silicon ingot includes: solidifying a silicon melt retained in a crucible unidirectionally upward from a bottom surface of the silicon melt, wherein a silicon nitride coating layer is formed on inner surfaces of side walls and an inner side surface of a bottom of the crucible, a solidification process in the crucible is divided into a first region from 0 mm to X (10 mm?X<30 mm) in hight, a second region from X to Y (30 mm?Y<100 mm), and a third region of the Y or higher, with the bottom of the crucible as a datum, a solidification rate V1 in the first region is in a range of 10 mm/h?V1?20 mm/h, and a solidification rate V2 in the second region is in a range of 1 mm/h?V2?5 mm/h.

Abstract: A group III nitride crystal containing therein an alkali metal element comprises a base body, a first group III nitride crystal formed such that at least a part thereof makes a contact with the base body, the first group III nitride crystal deflecting threading dislocations in a direction different from a direction of crystal growth from the base body and a second nitride crystal formed adjacent to the first group III nitride crystal, the second nitride crystal having a crystal growth surface generally perpendicular to the direction of the crystal growth.

Abstract: The processes are utilized to recover ammonium from waste water using CO2 acidified absorption water. The process is particularly suited for utilization of cellular matter and a CO2 rich tail gas from a syngas fermentation process and derives significant benefit from the recovery of ammonium bicarbonate and ammonium carbonate. Ammonia and ammonium are recovered from the treatment of the syngas as an ammonium rich solution, at least a portion of which is recycled to the fermentation zone to aid in the production of liquid products. A carbon dioxide rich gas produced by fermentation is used to capture the ammonia and ammonium, forming the ammonium rich solution.

Abstract: A material with cationic exchanger properties is introduced into aqueous media, where the equilibriums of carbon dioxide dissolution take place. A cationic exchanger material x/nM+nEx? is used to capture hydronium cations (H3O+) according to: x/nM+nEx?(s)+xH3O+(aq)=xH3O+Ex?(s)+x/nM+n(aq) where “x” stands for molar amount of the anionic centers of charge of the cationic exchanger material Ex? balanced by x/n molar amount of metal M, “n” stands for the metal valence, and M is selected from the group consisting of 1A and/or 2A of the periodic table of elements. This capture of the hydronium cations, H3O+, shifts certain reaction equilibriums to the right, according to Le Chatelier's principle, producing more bicarbonate, HCO3?, and/or carbonate, CO3=, than would otherwise be obtained.

Abstract: Disclosed herein is a method of growth of enhanced adhesion MWCNTs on a substrate, referred to as the HGTiE process, the method comprising: chemical vapor deposition of an adhesive underlayer composed of alumina on a substrate composed of titanium or similar; chemical vapor deposition of a catalyst such as a thin film of iron on top of the adhesive underlayer; pretreatment of the substrate to hydrogen at high temperature; and exposure of the substrate to a feedstock gas such as ethylene at high temperature. The substrate surface may be roughened before placement of an adhesive layer through mechanical grinding or chemical etching. Finally, plasma etching of the MWCNT film may be performed with oxygen plasma. This method of growth allows for high strength adhesion of MWCNTs to the substrate the MWCNTs are grown upon.

Abstract: A method of increasing the density of carbon nanotube fibres or films containing carbon nanotubes to at least 50% w/w, said method including the steps of exposing the fibre or film to suitable density enhancing agent.

Abstract: A known method for producing a porous carbon body comprises providing a template of inorganic template material which comprises interconnected pores, providing a precursor substance for carbon, infiltrating the pores of the template with the precursor substance, carbonizing the precursor substance and removing the template with formation of the porous carbon product. Starting therefrom, to provide a method which allows a cost-effective production of a porous carbon structure also with thick wall thicknesses, it is suggested according to the invention that precursor substance particles of fusible material and template particles are provided and a powder mixture is formed from the particles, and that the powder mixture is heated before or during carbonization according to method step (d) in such a manner that precursor substance melt penetrates into the pores of the template particles.

Abstract: The present invention provides an organic phase composition comprising: (a) a first solvent (S1) characterized by a water solubility of less than 10% and by at least one of (a1) having a polarity related component of Hoy's cohesion parameter (delta-P) between 5 and 10 MPa1/2 and (b1) having a Hydrogen bonding related component of Hoy's cohesion parameter (delta-H) between 5 and 20 MPa1/2; (b) a second solvent (S2) characterized by a water solubility of at least 30% and by at least one of (a2) having a delta-P greater than 8 MPa1/2 and (b2) having a delta-H greater than 12 MPa1/2; (c) water; (d) HCl; and (e) a carbohydrate.

Abstract: The present invention provides an organic phase composition comprising (f) a first solvent (S1) characterized by water solubility of less than 10% and by at least one of (a1) having a polarity related component of Hoy's cohesion parameter (delta-P) between 5 and 10 mPa1/2 and (b1) having a Hydrogen bonding related component of Hoy's cohesion parameter (delta-H) between 5 and 20 MPa1/2; (g) a second solvent (S2) characterized by water solubility of at least 30% and by at least one of (a2) having a delta-P greater than 8 MPa1/2 and (b2) having a delta-H greater than 12 MPa1/2; (h) water (i) HCl, and (j) a chloride salt.

Abstract: A process for the production of a synthesis gas containing hydrogen and carbon monoxide utilizes ground coke having a predetermined ash content in combination with a refinery residual hydrocarbon oil feedstream for gasification in the combustion chamber of a tubular wall membrane partial oxidation gasification reactor in the presence of a predetermined amount of oxygen; the coke and residual oil can be mixed to form a single feedstream or introduced into the reactor as separate feeds. Optionally, the product synthesis gas is introduced as the feedstream to a water-gas shift reactor to enhance the hydrogen content of the final product stream.

Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.

Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.

Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Abstract: This invention relates to radioactive tyrosine derivatives for imaging bone metastases, a method for imaging or diagnosing bone metastases, compositions and kits for imaging bone metastases.

Abstract: An encapsulated surface enhanced Raman scattering (SERS) tag. The tag includes a metal core and an encapsulant, typically a glass encapsulant. The encapsulant is further derivatized with a polymer.

Abstract: A method involving ion milling is demonstrated to fabricate open-nanoshell suspensions and open-nanoshell monolayer structures. Ion milling technology allows the open-nanoshell geometry and upward orientation on substrates to be controlled. Substrates can be fabricated covered with stable and dense open-nanoshell monolayer structures, showing nanoaperture and nanotip geometry with upward orientation, that can be used as substrates for SERS-based biomolecule detection.

Abstract: To provide a mixing device, a mixing tube, a drug solution injecting system, and a drug solution mixing method capable of evenly and efficiently mixing a plurality of kinds of drug solutions. The mixing device according to the present invention includes: a swirling flow generating chamber; a first inflow opening for introducing a first drug solution into the swirling flow generating chamber in a direction parallel to a central axis of the swirling flow; a second inflow opening for introducing a second drug solution into the swirling flow generating chamber so as to generate a swirling flow of the second drug solution having a specific gravity lower than that of the first drug solution; an outflow opening for discharging a mixed drug solution; and a narrowing chamber which is interposed between the swirling flow generating chamber and the outflow opening and has a space continuously narrowed toward the outflow opening.

Abstract: The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the pro drug to treat certain disorders, and optionally one or more other active agents are provided by the invention.

Abstract: The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to compounds binding specifically to this active site of kallikrein 7.

Abstract: The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin.

Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.

Abstract: The present invention relates to the field of improving the flavour of foodstuffs, beverages, tobacco products, pharmaceutics and oral care products. More particularly, the present invention provides flavour modulating substances selected from the group represented by formula (I): and edible salts thereof and edible esters thereof, which can advantageously be used for modulating the flavour of foodstuffs, beverages, tobacco products, pharmaceutics and oral care products. These flavour modulating substances can be used to impart desirable taste attributes in a wide variety of applications and products. In addition, the present flavour modulating substances are capable of modulating the taste and/or aroma impact of other, flavour imparting, substances contained within these same products, thereby improving the overall flavour quality of these products.

Abstract: The invention provides a method of preventing, inhibiting or reducing a P. gingivalis biofilm in a subject comprising administering to the subject a pharmaceutical composition comprising an inhibiting agent of a polypeptide that reduces or inhibits biofilm formation and/or biofilm development. Also provided are compositions useful in the prevention, inhibition or treatment of periodontal disease or P. gingivalis infection.

Abstract: A method for blocking, neutralizing, or killing microorganisms that cause infectious disease in a mammal prior to or during the mammal encountering a contaminated environment or item includes: identifying a contaminated environment or item, wherein the contaminated environment or item is known or expected to be contaminated with harmful viral, fungal, or bacterial microorganisms; and administering a therapeutically effective amount of a barrier-forming composition to a mucosa of the mammal prior to or during the mammal encountering the contaminated environment or item. The barrier-forming composition provides a barrier on the mucosa that inhibits the microorganisms from contacting the mucosa. Other related methods are also included.

Abstract: The present invention concerns a novel agent which is capable of stimulating the expression of LOXL and of increasing quality and functionality of collagen fibres and has anti-oxidizing, anti-elastase, anti-MMP properties as well as its use in producing cosmetic or pharmaceutical compositions, especially dermatological compositions, or food compositions.

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline

Abstract: Compositions for the protection of an object from UV light are provided. For example, in certain aspects, the compositions can include a plurality of silicone-containing compounds that improve the aesthetic properties.

Abstract: A oil-in-water emulsion composition which contains a low solubility but oil-soluble ultraviolet absorber. and which exhibits superior stability. The composition contains (a) an aqueous dispersion of an oil-soluble ultraviolet absorber; (b) a compound of a non-ionic surfactant and at least one type of fatty acid soap; (c) a water-swelling clay mineral: and (d) a higher fatty acid. Component (a) is preferably an aqueous dispersion of a complex particle of an oil-soluble ultraviolet absorber and an organic polymer.

Abstract: Methods and composition for the protection of an object from UV light are provided. For example, in certain aspects, the composition can include a plurality of photo stabilizers that enhance SPF values of the composition. Furthermore, the invention provides for the use of the compositions.

Abstract: The present invention discloses a method to inhibit a free radical, including a mitochondrial free radical, comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of formula (I: a, b), an isomer, or a salt thereof:

Abstract: Soft solid antiperspirant compositions are provided. In accordance with an exemplary embodiment, an antiperspirant composition comprises an active antiperspirant compound, a first fatty alcohol constituent comprising stearyl alcohol, and a second fatty alcohol constituent comprising C14 to C16 fatty alcohol. The exemplary soft solid antiperspirant composition has a first fatty alcohol to second fatty alcohol ratio of from about 2:1 to about 6:1.

Abstract: Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.

Abstract: This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise polymers that comprise at least two immunomodulatory agent moieties.

Abstract: The invention disclosed relates to a novel composition and use thereof, for the attraction and detection of emerald ash borer, Agrilus planipennis Fairmaire. The composition comprises (3Z)-dodecen-12-olide and ash foliar or cortical volatiles (green leaf volatiles) associated with a prism trap of a color in the green range of the visible light spectrum. A significant increase in the capture of male A. planipennis is achieved when traps were deployed in the upper tree canopy. This invention is the first demonstration of increased attraction with a combination of a pheromone and a green leaf volatile in a Buprestid species.

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.

Abstract: The present invention relates to a cytokine for use in the treatment and/or control of dependent and/or addictive behavior, in particular addiction and/or dependency to nicotine, food addiction, alcohol addiction and/or sex addiction. The present invention also relates to treatment and/or control of withdrawal and/or symptoms of withdrawal from an addiction, in particular nicotine addiction, food addiction, alcohol addiction and/or sex addiction. The present invention further relates to the induction of loss of interest or aversion to the addictive substance or behavior, such as nicotine, over-indulgence in high-calorie, high-fat foods, and to other behaviors or addictions that are hazardous to the health.

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.

Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containing one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRR, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.